drugset / Trial / NCT03699956
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
RandomizedCrossoverOpen-labelTreatment
Summary
This Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.
Timeline
- Start
- 2018-12-24
- Primary completion
- 2022-08-11
- Completion
- 2024-03-01
Publications
- Jayabalan N, Oronsky B, Cabrales P, Reid T, Caroen S, Johnson AM, Birch NA, O'Sullivan JD, Gordon R. A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation. Drugs. 2023 Apr;83(5):389-402. doi: 10.1007/s40265-023-01838-z. Epub 2023 Mar 15.
- Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019 Oct;15(30):3427-3433. doi: 10.2217/fon-2019-0317. Epub 2019 Sep 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIBROZETONE | Other / unclassified | 4 mg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | 60 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |